Seeking Alpha

PDL BioPharma acquires royalty, milestone rights from Depomed in $240.5M deal

  • PDL BioPharma (PDLI) acquires royalty and milestone rights on sales of Type 2 diabetes products licensed by Depomed (DEPO).
  • PDLI is paying $240.5M in cash and will receive all royalty and milestone payments up to $481M, after which time the two companies will split payments.
  • The rights acquired are tied to: Glumetza, Janumet XR, Invokana, among other products. (PR)
Comments (1)
  • casenundra
    , contributor
    Comments (22) | Send Message
    And they said there was no life after Queen et al expired.
    22 Oct 2013, 11:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: